Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma

被引:4
|
作者
Liu, Hangqi [1 ]
Zhang, Zhiwen [1 ]
Chen, Longyun [1 ]
Pang, Junyi [1 ]
Wu, Huanwen [1 ]
Liang, Zhiyong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Mol Pathol Res Ctr, Dept Pathol,State Key Lab Complex Severe & Rare D, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ovarian clear cell carcinoma; homologous recombination repair gene; homologous recombination deficiency; molecular classification; next-generation sequencing; EXPRESSION; VARIANTS;
D O I
10.3389/fonc.2021.798173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endometrial carcinoma (EC) is potentially applicable in OCCC. In this study, surgically resected samples were collected from 44 patients with OCCC. Genomic alterations were determined using next-generation sequencing. HRD was estimated by genomic instability. Of 44 patients with OCCC, two (4.5%) harbored likely pathogenic mutations in HRR genes. Notably, no pathogenic or likely pathogenic mutations were found in BRCA1/2. A total of 24 variants of uncertain significance (VUS) in HRR-related genes occurred in 18 (40.9%) patients. HRD was observed in only one case (2.3%). In addition, TP53 mutation and microsatellite instability-high (MSI-H) were identified in three patients (6.8%) and in one patient (2.3%), respectively. TP53 mutation was significantly associated with disease-free survival and overall survival. No POLE mutations were found. In conclusion, our results revealed a very low prevalence of HRR gene mutations and HRD in OCCC. Moreover, TP53 mutations and MSI-H are uncommon, while POLE mutations are extremely rare in OCCC. Our findings indicate that the evaluation of HRR gene mutations, HRD status, POLE mutations, and MSI-H may have limited clinical significance for OCCC treatment and prognostic stratification.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] NEXT GENERATION SEQUENCING REVEALS A HIGH PREVALENCE OF PATHOGENIC MUTATIONS IN HOMOLOGOUS RECOMBINATION DNA DAMAGE REPAIR GENES AMONG PATIENTS WITH UTERINE SARCOMA
    Nasioudis, Dimitrios
    Latif, Nawar
    Ko, Emily
    Cory, Lori
    Haggerty, Ashley
    Kim, Sarah
    Morgan, Mark
    Simpkins, Fiona
    Giuntoli, Robert, II
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A6 - A7
  • [2] Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma
    Nasioudis, Dimitrios
    Latif, Nawar A.
    Ko, Emily M.
    Cory, Lori
    Kim, Sarah H.
    Martin, Lainie
    Simpkins, Fiona
    Giuntoli II, Robert
    GYNECOLOGIC ONCOLOGY, 2023, 177 : 14 - 19
  • [3] Landscape of homologous recombination repair (HRR) mutations in prostate cancer profiled by ctDNA next-generation sequencing
    Yen, Jennifer
    Gnerre, Sante
    Barbacioru, Catalin
    Helman, Elena
    Manor, Ohad
    Yablonovitch, Arielle
    Satya, Ravi Vijaya
    Liu, Leo
    Saam, Jennifer
    Fairclough, Stephen
    Nagy, Becky
    Lanman, Richard
    Talasaz, Darya Chudova AmirAli
    CANCER RESEARCH, 2020, 80 (16)
  • [4] Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer
    Song, Yaolin
    Ran, Wenwen
    Jia, Huiqing
    Yao, Qin
    Li, Guangqi
    Chen, Yang
    Wang, Xiaonan
    Xiao, Yujing
    Sun, Mengqi
    Lu, Xiao
    Xing, Xiaoming
    HELIYON, 2024, 10 (02)
  • [5] Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing
    Zhao, Qianying
    Yang, Jiaxin
    Li, Lei
    Cao, Dongyan
    Yu, Mei
    Shen, Keng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (04)
  • [6] Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing
    Jiang, Huiqin
    Huang, Fei
    Chen, Xinning
    Zhang, Li
    Shen, Minna
    Pan, Baishen
    Wang, Beili
    Guo, Wei
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2023, 11 (07):
  • [7] YEvaluation of Homologous Repair Deficiency Status in Ovarian Carcinoma Using In-House Next-Generation Sequencing Panels
    Seth, A.
    Hussain, M.
    Jhala, N.
    Belogrivtseva, Y.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S93 - S94
  • [8] Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Epithelial Ovarian Carcinoma
    Bartow, Brooke
    Chang, Jeffrey
    Siegal, Gene
    Arend, Rebecca
    Kahn, Andrea
    Al Diffalha, Sameer
    Mackinnon, Alexander
    Pesoli, Christine
    Harada, Shuko
    Huang, Xiao
    LABORATORY INVESTIGATION, 2023, 103 (03) : S859 - S860
  • [9] The landscape of homologous recombination repair gene mutations and prognosis in Chinese patients with clear cell renal cell carcinoma
    Chen, Peng
    Zhang, Yuan
    Bi, Xing
    Niu, Yue
    Shayiti, Fuerhaiti
    Yuan, Shuai
    Pan, Ting
    Wang, Yan
    CANCER RESEARCH, 2022, 82 (12)
  • [10] CONCORDANCE OF THE FDA-APPROVED COMPANION DIAGNOSTIC AND A NEXT-GENERATION SEQUENCING ASSAY KIT FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN OVARIAN CANCER
    Weichert, W.
    Qiu, P.
    Lunceford, J.
    Wehn, A.
    Yarunin, A.
    Marton, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A375 - A375